A Food and Drug Administration-approved asthma therapeutic agent impacts amyloid β in the brain in a transgenic model of Alzheimer disease.
Academic Article
- Overview
- Research
- Identity
- Additional document info
- View All
Overview
publication date
- December 2, 2014